Quick Summary
CAR-T cell therapy in China is available at NMPA-approved facilities for specific blood cancers, at costs 50–70% below US and Western European private rates. Manufacturing timelines have been compressed to as little as 24–36 hours at some centres. This is a genuinely viable option for eligible patients — but eligibility criteria are strict and the process requires careful coordination.
- →NMPA-approved CAR-T products available for B-cell lymphoma and multiple myeloma
- →Cost in China: approximately €40,000–€80,000 vs €200,000–€400,000 in the US
- →Manufacturing timeline: 24–36 hours at advanced centres vs 3–6 weeks conventionally
- →Eligibility: typically relapsed/refractory disease after 2+ prior lines of treatment
- →Clinical trials offer access to next-generation products not yet available in Europe
CAR-T therapy is a complex, high-risk treatment that must be administered at specialist centres under close medical supervision. This article provides factual information only. Eligibility and suitability must be assessed by a qualified oncologist. This is not medical advice.
Why International Patients Are Choosing China for CAR-T
CAR-T cell therapy — chimeric antigen receptor T-cell therapy — is one of the most significant advances in cancer treatment in decades. In Europe, access is tightly controlled: NHS coverage is limited to specific indications, and private rates in the UK and Germany reach €200,000–€400,000 per infusion. China has emerged as a leading alternative for three reasons:
- Cost: NMPA-approved CAR-T products in China cost approximately €40,000–€80,000 for international patients — 50–70% below Western commercial rates
- Speed: advanced Chinese manufacturing platforms have compressed T-cell production from the conventional 3–6 weeks to as little as 24–36 hours, critical for patients with rapidly progressing disease
- Access: China has approved multiple CAR-T products and has one of the largest CAR-T clinical trial programmes in the world, offering access to next-generation therapies not yet available in Europe
NMPA-Approved CAR-T Products in China (2026)
The following CAR-T products have received approval from China's National Medical Products Administration (NMPA) as of 2026. Only NMPA-approved products at regulated facilities should be considered — do not seek CAR-T therapy at unverified clinics.
| Product | Manufacturer | Indication | Status |
|---|---|---|---|
| Relma-cel (relmacabtagene autoleucel) | JW Therapeutics | Relapsed/refractory large B-cell lymphoma (LBCL) | NMPA approved |
| Yescarta (axicabtagene ciloleucel) | Fosun Kite (China) | Relapsed/refractory LBCL | NMPA approved |
| Equecabtagene autoleucel (CT053) | CARsgen Therapeutics | Relapsed/refractory multiple myeloma (MM) | NMPA approved |
| Ciltacabtagene autoleucel (Carvykti) | Legend Biotech / JW Therapeutics | Relapsed/refractory multiple myeloma | NMPA approved |
| Satri-cel | CARsgen Therapeutics | Claudin18.2+ gastric/GEJ adenocarcinoma | NDA accepted 2025, pending approval |
Beyond approved products, China has one of the world's largest CAR-T clinical trial programmes — covering solid tumours, additional haematological cancers, and next-generation CAR constructs. Eligible patients may access investigational products through hospital-sponsored trials at research centres including Peking University Cancer Hospital and the Chinese PLA General Hospital.
Who Is Eligible for CAR-T Therapy?
Eligibility for approved CAR-T products in China follows similar criteria to European and US approvals. Patients typically must meet all of the following:
- Confirmed diagnosis of an approved indication (B-cell lymphoma or multiple myeloma for currently approved products)
- Relapsed or refractory disease: the cancer has returned after, or did not respond to, at least two prior lines of systemic therapy
- Adequate organ function: heart, kidneys, liver, and lungs must meet minimum function thresholds assessed by blood tests and imaging
- Performance status: patients must be well enough to undergo the conditioning chemotherapy and infusion process
- No active uncontrolled infection at the time of treatment
- Age: most programmes accept adults 18+; some paediatric programmes exist within trials
Eligibility for clinical trial products is assessed on a case-by-case basis and may differ from the above. Your coordinator will submit your medical records for review by the hospital's oncology team before confirming eligibility.
Cost of CAR-T Therapy in China vs Other Countries
| Country | Approximate Cost (International Patient) | Notes |
|---|---|---|
| United States | €200,000–€400,000 | Commercial rate, uninsured or out-of-network |
| United Kingdom | NHS funded for specific indications; private: €150,000–€300,000 | NHS access tightly controlled; long approval process |
| Germany | GKV may cover approved products; private: €180,000–€350,000 | Approval process can take months |
| China (approved product) | €40,000–€80,000 | International patient rate; includes hospital stay |
| China (clinical trial) | Reduced or no drug cost in some trials | Trial eligibility criteria apply |
The CAR-T Treatment Journey in China
CAR-T therapy is not a single appointment — it is a 4–8 week process requiring close medical supervision. Here is what to expect as an international patient:
Step 1 — Case Review (2–4 weeks before travel)
Submit medical records, pathology reports, imaging, and treatment history to your coordinator. The hospital's oncology team reviews eligibility and confirms a treatment plan. This happens remotely before you travel.
Step 2 — T-Cell Collection (Leukapheresis)
On arrival, your T-cells are collected via leukapheresis — a 3–4 hour outpatient procedure where blood is drawn, T-cells are extracted, and the remaining blood is returned to your body. At advanced Chinese centres, manufacturing begins within hours of collection.
Step 3 — Manufacturing (24 hours to 6 weeks)
Your T-cells are genetically engineered to express chimeric antigen receptors targeting your cancer. Conventional manufacturing takes 3–6 weeks; next-generation platforms at leading Chinese centres have achieved 24–36 hours. During this period, patients typically remain near the hospital or complete bridging therapy if required.
Step 4 — Conditioning Chemotherapy
Before the CAR-T infusion, patients receive a short course of lymphodepleting chemotherapy (typically fludarabine and cyclophosphamide) to prepare the immune system. This takes 3–5 days and requires hospitalisation.
Step 5 — CAR-T Infusion
The engineered T-cells are infused intravenously — typically a 30–60 minute procedure. Patients remain hospitalised for monitoring for at least 7–14 days post-infusion.
Step 6 — Monitoring and Follow-up
The critical monitoring period is the first 30 days post-infusion, when cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) — the two main serious side effects — are most likely to occur. Patients should plan to remain in China for at least 4–6 weeks total. Ongoing follow-up (blood tests, imaging) continues after return home, coordinated with your home oncologist.
Considering treatment in China?
Submit a free, confidential assessment and receive a personalised treatment roadmap within 24 hours — at no cost to you.
Get Your Free AssessmentSide Effects and Safety
CAR-T therapy carries significant risks that must be understood before proceeding. The two most serious potential side effects are:
Cytokine Release Syndrome (CRS)
CRS occurs when the engineered T-cells rapidly activate and release large amounts of immune signalling molecules. Symptoms range from fever and fatigue (mild, Grade 1–2) to hypotension, organ dysfunction, and respiratory failure (severe, Grade 3–4). CRS occurs in 40–90% of patients to some degree; severe CRS in 10–30%. It is manageable with tocilizumab and corticosteroids at experienced centres, but requires immediate medical response. This is why CAR-T must only be administered at specialist centres with ICU capability.
Neurotoxicity (ICANS)
Immune effector cell-associated neurotoxicity syndrome can cause confusion, speech difficulty, seizures, and in rare cases cerebral oedema. It typically occurs 5–14 days post-infusion. Grade 3–4 ICANS occurs in 10–30% of patients depending on the product and indication. It is treatable but requires experienced neurological monitoring.
How to Access CAR-T Therapy in China
- Submit a case assessment with full medical records, pathology, and treatment history
- Your coordinator forwards to specialist oncology teams at appropriate centres
- Eligibility confirmation typically within 1–2 weeks
- Travel planning begins once eligibility is confirmed — plan for a minimum 5–6 week stay
- Coordinate with your home oncologist: they should be informed and involved in post-treatment monitoring
Frequently Asked Questions
How much does CAR-T therapy cost in China?
For international patients at NMPA-approved facilities in China, CAR-T therapy typically costs €40,000–€80,000, including the T-cell manufacturing, infusion, and hospital stay. This compares to €200,000–€400,000 in the US for equivalent commercial products. Costs vary by product, indication, and hospital. Some clinical trial programmes offer reduced or zero drug costs for eligible patients, though trial eligibility criteria are strict.
Which cancers can be treated with CAR-T therapy in China?
NMPA-approved CAR-T products in China currently cover: relapsed or refractory large B-cell lymphoma (LBCL) — treated with Relma-cel or Yescarta; and relapsed or refractory multiple myeloma — treated with Equecabtagene autoleucel or Ciltacabtagene autoleucel (Carvykti). Clinical trial programmes at major research hospitals are investigating CAR-T for additional indications including other B-cell malignancies, T-cell lymphomas, and selected solid tumours (gastric, lung). Submit your records for assessment to determine if a programme exists for your specific diagnosis.
How long does CAR-T treatment take in China?
Plan for a total stay of 5–8 weeks in China. The process involves: T-cell collection on arrival (1 day), manufacturing (24 hours to 6 weeks depending on the platform), conditioning chemotherapy (3–5 days), CAR-T infusion and immediate monitoring (7–14 days hospitalisation), and post-infusion monitoring period before travel clearance (typically 2–4 weeks). Your coordinator will give you a timeline based on the specific product and centre.
Is CAR-T therapy available on the NHS?
Yes, for specific indications — but access is tightly controlled. NHS England funds CAR-T (via NHS Highly Specialised Services) for certain haematological cancers including large B-cell lymphoma and multiple myeloma, but only at designated treatment centres and subject to individual funding review. Approval processes can take months. Some patients choose China to access treatment faster or for indications not yet funded by the NHS.
What are the risks of CAR-T therapy?
CAR-T therapy carries two main serious risks: Cytokine Release Syndrome (CRS) — an immune overreaction causing fever, low blood pressure, and in severe cases organ dysfunction — occurs in 40–90% of patients to some degree, with severe CRS in 10–30%. Neurotoxicity (ICANS) — causing confusion, speech difficulty, and seizures — occurs in 10–30% of patients in severe form. Both are manageable at experienced centres with appropriate supportive care, but require immediate access to ICU and specialist oncology teams. This is why CAR-T must only be administered at accredited specialist centres.
Related Guides
Ready to Explore Your Options?
Submit a free, confidential assessment. A coordinator will provide a personalised treatment plan within 24 hours.
Get Your Free Assessment